Document Detail

Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.
MedLine Citation:
PMID:  21933674     Owner:  NLM     Status:  MEDLINE    
This study investigated whether PRM-151 (Promedior, Inc., Malvern, PA), a recombinant form of human pentraxin-2 (PTX-2, also referred to as serum amyloid P, hSAP), that inhibits differentiation of circulating monocytes into fibrocytes and profibrotic macrophages, could modulate generation of myofibroblasts after opacity-producing corneal injury in rabbits, and, therefore, have potential to reduce or prevent haze after PRK. Nine diopter PRK for myopia was performed with the VISX S4 IR laser. Four groups of 6 animals were treated in masked fashion: Group 1: 30 μl of topical PRM-151 (20 mg/ml) 6 times a day for 5 days; Group 2: 30 μl topical vehicle 6 times a day for 5 days; Group 3: 200 μl sub-conjunctival PRM-151 (total injection of 4 mg) immediately after surgery and every other day until day 8; Group 4: 200 μl sub-conjunctival injections of vehicle according to the same schedule as group 3. At one month after PRK, the animals were euthanized and immunohistochemistry was performed for the myofibroblast marker α-smooth muscle actin (SMA). The density of SMA+ cells/400× field in the central stroma was determined in each cornea. Myofibroblast density at one month after surgery was significantly lower (p = 0.006) after sub-conjunctival PRM-151 treatment (5.8 ± 2.8 cells/400× stromal field) compared to sub-conjunctival vehicle treatment (15.3 ± 2.9 cells/400× stromal field). There was no significant (p = 0.27) decrease in stromal myofibroblasts triggered by topical PRM-151 treatment (11.8 ± 6.6 cells/400× stromal field) compared to the topical vehicle treatment (14.2.8 ± 6.2 cells/400× stromal field). PRM-151 inhibits myofibroblast generation when administered by sub-conjunctival injection, but not when administered topically, after opacity-producing corneal injury. This study provides additional confirmation that bone marrow-derived cells contribute to corneal myofibroblast generation.
M R Santhiago; V Singh; F L Barbosa; V Agrawal; S E Wilson
Related Documents :
20452254 - Occurrence of bad splits during sagittal split osteotomy.
9506294 - Information on infraorbital nerve damage from multitesting of sensory function.
16818154 - The spike osteotomy for hallux valgus: a clinical and radiological evaluation.
17174764 - Transverse displacement of the proximal segment after bilateral sagittal split osteotom...
17541664 - Moving beyond empiric continuous positive airway pressure (cpap) trials for central sle...
12194554 - Adjustable gastric and esophagogastric banding: a randomized clinical trial.
Publication Detail:
Type:  Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-09-14
Journal Detail:
Title:  Experimental eye research     Volume:  93     ISSN:  1096-0007     ISO Abbreviation:  Exp. Eye Res.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-21     Completed Date:  2012-02-03     Revised Date:  2014-09-15    
Medline Journal Info:
Nlm Unique ID:  0370707     Medline TA:  Exp Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  786-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actins / metabolism
Cell Count
Cell Differentiation / drug effects
Cornea / injuries
Corneal Opacity / metabolism,  prevention & control*
Corneal Stroma / drug effects*,  metabolism
Fluorescent Antibody Technique, Indirect
Homeodomain Proteins / administration & dosage*
Injections, Intraocular
Lasers, Excimer
Monocytes / drug effects*
Myofibroblasts / metabolism*
Myopia / surgery
Photorefractive Keratectomy
Recombinant Proteins / administration & dosage
Serum Amyloid P-Component / administration & dosage*
Grant Support
EY015638/EY/NEI NIH HHS; EY10056/EY/NEI NIH HHS; R01 EY010056/EY/NEI NIH HHS; R01 EY010056-18/EY/NEI NIH HHS
Reg. No./Substance:
0/Actins; 0/Homeodomain Proteins; 0/PRM-151; 0/Recombinant Proteins; 0/Serum Amyloid P-Component

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
Next Document:  Competitive binding to plasma thyroid hormone transport proteins and thyroid disruption by phenylbut...